Ftse Mib
33.783,55
0,14%
DAX
17.967,90
0,35%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.129,04
0,01%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Addex Therapeutics Ltd (ADXN) Addex Therapeutics Ltd (ADXN) Notizie

Addex Therapeutics Ltd

ADXN
8,83
-0,02 (-0,23%)
Pre Mercato
Ultimo aggiornamento: 13:16:54
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/4/202407:00GLOBEAddex Provides Update on ADX71149 Phase 2 Epilepsy Study
19/4/202407:00GLOBEAddex to Present at the Swiss Biotech Day 2024
18/4/202407:00GLOBEAddex Therapeutics Reports Full Year 2023 Financial Results..
11/4/202407:00GLOBEAddex Therapeutics to Release Full-Year 2023 Financial..
03/4/202407:00GLOBEAddex and Perceptive Launch Neurosterix with $63 Million to..
14/3/202407:00GLOBEAddex to Present at the Bio-Europe Spring 2024 Conference
31/1/202407:00GLOBEAddex Enters into At-The-Market ADS Offering Agreement with..
30/1/202423:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/1/202422:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202407:00GLOBEAddex to Present at the Swiss Equities Baader Conference
05/1/202407:30GLOBEAddex to Present at Biotech Showcase™ 2024
21/12/202312:00EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
20/12/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202307:00GLOBEAddex Shareholders Approve All Resolutions at Extraordinary..
14/12/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202307:00GLOBEAddex Creates Treasury Shares
08/12/202320:11EDGAR2Form SC 13D/A - General statement of acquisition of..
30/11/202322:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
30/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
29/11/202322:00EDGAR2Form SC 13D/A - General statement of acquisition of..
29/11/202312:27EDGAR2Form POS AM - Post-Effective amendments for registration..
29/11/202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202307:00GLOBEAddex Reports Q3 2023 Financial Results and Provides..
28/11/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202307:00GLOBEAddex Convenes Extraordinary General Meeting
23/11/202307:00GLOBEAddex Therapeutics to Release Third Quarter 2023 Financial..
14/11/202307:00GLOBEAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment..
08/11/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202307:00GLOBEAddex Regains Nasdaq Listing Compliance
02/11/202307:00GLOBEAddex Announces Participation in the Bio-Europe 2023..
23/10/202312:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/10/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/10/202307:00GLOBEAddex Completes ADS Ratio Change
06/10/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202322:00GLOBEAddex Announces Plan to Implement ADS Ratio Change
20/9/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202307:00GLOBEAddex mGlu2 NAM Cognition Program Receives €4 Million Grant
06/9/202307:00GLOBEAddex Announces Participation in the H.C. Wainwright 25th..
05/9/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202307:00GLOBEAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout..
04/9/202307:00GLOBEAddex’s Dipraglurant Development in Post-Stroke Recovery..
11/8/202322:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/8/202322:00EDGAR2Form POS AM - Post-Effective amendments for registration..
10/8/202312:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202307:00GLOBEAddex Reports 2023 Half Year and Second Quarter Financial..
04/8/202307:00GLOBEAddex Therapeutics to Release Half-Year 2023 Financial..
03/8/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202307:00GLOBEAddex GABAB Positive Allosteric Modulator Program to Receive..
24/7/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: Min: Max:
Chiusura: 8,85

La tua Cronologia

NASDAQ
ADXN
Addex Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network